Seventh Amendment Requires a Jury for FDCA/TCA Civil-Penalty Enforcement Against Vape Sellers (Limiting the Public-Rights Exception)

Case: Texas Tobacco Barn v. HHS
Court: United States Court of Appeals for the Fifth Circuit
Date: June 30, 2026
Disposition: Petition granted; HHS civil-penalty order vacated on Seventh Amendment grounds.

I. Introduction

Texas Tobacco Barn, L.L.C. (doing business as TXVapeBarn) challenged a $19,192 civil monetary penalty imposed after a juryless administrative adjudication within the Department of Health & Human Services (HHS). HHS (through FDA’s Center for Tobacco Products) alleged that the company sold “unauthorized” e-liquid vape products—specifically variants of “Barn Brewed Beetle Juice”—without the premarket authorization required by the Family Smoking Prevention and Tobacco Control Act (TCA) as integrated into the Food, Drug, and Cosmetic Act (FDCA).

The case presented three core issues: (1) whether the TCA’s “deeming provision” unconstitutionally delegated legislative power to FDA; (2) whether imposing FDCA/TCA civil penalties through an HHS administrative process without a jury violates the Seventh Amendment, especially after SEC v. Jarkesy; and (3) whether the agency’s findings were supported by substantial evidence.

The Fifth Circuit rejected the nondelegation challenge as foreclosed by circuit precedent, but held that the Seventh Amendment required a jury trial because the enforcement action sought punitive civil penalties analogous to common-law remedies and the “public rights” exception did not apply.

II. Summary of the Opinion

The Fifth Circuit (Judge Duncan, joined by Judge Jones) held:

  • Nondelegation: The TCA’s deeming provision remains constitutional under Fifth Circuit precedent (Big Times Vapes, Inc. v. FDA), and the challenge could not be reframed as a “major questions doctrine” claim.
  • Seventh Amendment: The HHS civil-penalty proceeding denied TTB’s jury-trial right. The monetary penalty is “the prototypical common law remedy” aimed at punishment/deterrence, and the statutory claim is sufficiently analogous to common-law actions policing adulterated/unwholesome goods and deceptive sales practices.
  • Public-rights exception: HHS failed to show a historically grounded category permitting agency adjudication of this type of civil-penalty enforcement; generalized appeals to “public health” regulation were insufficient.
  • Relief: Petition granted and agency decision vacated; the court did not reach the substantial-evidence challenge.

Dissent (Judge Douglas): Agreed the Seventh Amendment is implicated but would apply the public-rights exception because the specific “failure-to-preauthorize” enforcement action is a novel regulatory requirement without a close common-law analogue, more akin to public-rights regimes sustained in older administrative-law cases.

III. Analysis

A. Precedents Cited

1) The tobacco/vape regulatory backdrop

  • FDA v. Brown & Williamson Tobacco Corp. (2000): The Supreme Court held the FDCA did not authorize FDA to regulate tobacco as then structured. The Fifth Circuit uses it to explain why Congress enacted the TCA to confer express tobacco authority, including FDA’s power to “deem” additional products within the definition of “tobacco product.”
  • FDA v. Wages & White Lion Invs., L.L.C. (2025) and White Lion Invs. (as quoted in the opinion): Cited for the modern authorization framework and for the proposition that the deeming provision grants “explicit[]” authority. This undermined TTB’s attempt to invoke the major-questions doctrine by portraying FDA’s vape authority as resting on ambiguity.
  • FDA v. R.J. Reynolds Vapor Co. (2025): Used for the procedural point that targets of HHS civil-penalty orders may seek circuit-court review under 21 U.S.C. § 333(f)(6).

2) Nondelegation and major questions

  • J.W. Hampton, Jr., & Co. v. United States (1928) and Mistretta v. United States (1989): Supply the “intelligible principle” framework. They are the doctrinal baseline for evaluating delegations to agencies.
  • Big Times Vapes, Inc. v. FDA (5th Cir. 2020): The controlling circuit precedent rejecting a nondelegation challenge to the same TCA deeming provision. The court treats it as dispositive: Congress defined “tobacco product,” established general policy, and sufficiently “circumscribed” FDA discretion.
  • VDX Distro, Inc. v. FDA (5th Cir. 2026): A near-direct on-point decision rejecting an “identical challenge” packaged as “major questions” but substantively nondelegation. The panel uses it to foreclose TTB’s reframing attempt.
  • West Virginia v. EPA (2022) and Learning Res., Inc. v. Trump (2026): The court cites these to define the major-questions doctrine as a constraint on agencies claiming broad power from statutory ambiguity. The Fifth Circuit then distinguishes this case: the deeming power is not ambiguous; it is explicit.

3) Standard of review and deference after Chevron’s demise

  • Loper Bright Enters. v. Raimondo (2024): Cited for de novo judicial resolution of legal questions, situating the case in the post-Chevron environment.
  • Tex. Clinical Labs, Inc. v. Sebelius (5th Cir. 2010): Used to place the burden of showing agency invalidity on the petitioner.

4) Seventh Amendment: when agency penalties require juries

  • SEC v. Jarkesy (2024): The opinion’s centerpiece. The court applies Jarkesy’s two-step Seventh Amendment inquiry—(i) remedy and (ii) cause-of-action analogy—then asks whether the “public rights” exception permits agency adjudication anyway.
  • Granfinanciera, S.A. v. Nordberg (1989): Provides the principle that the Seventh Amendment reaches statutory causes of action “legal in nature,” and anchors the “public rights” discussion.
  • Tull v. United States (1987): Reinforces that government actions seeking civil penalties historically required juries; also supports remedy-centric analysis.

5) Article III and the “public rights” exception

  • Stern v. Marshall (2011) and Murray's Lessee v. Hoboken Land & Improvement Co. (1856): Provide the canonical formulation that Congress cannot withdraw “private rights” from “judicial cognizance,” with “public rights” as a narrow historical exception.
  • N. Pipeline Constr. Co. v. Marathon Pipe Line Co. (1982): Cited (via Jarkesy) for the presumption favoring Article III courts even where public rights might arguably apply.
  • Intuit, Inc. v. FTC (5th Cir. 2026): A Fifth Circuit decision emphasizing that courts must not expand public rights beyond historical limits and must scrutinize each asserted application carefully.
  • Vaping Dragon LLC v. FDA (N.D. Tex. 2026): Cited for the proposition that Crowell v. Benson’s “public health” reference did not recognize public health as a distinct public-rights category.
  • The opinion lists examples often cited as public-rights domains, including Oceanic Steam Navigation Co. v. Stranahan, Ex parte Bakelite Corp., United States v. Jicarilla Apache Nation, Crowell v. Benson, and United States v. Duell, to illustrate the historically bounded categories.
  • Houston v. St. Louis Independent Packing Co. (1919) and Crowell v. Benson (1932): Invoked by HHS to argue “public health” adjudications can be administrative. The majority treats the “public health” reference in Crowell as dicta and finds Houston inapposite because it did not speak to Article III, the Seventh Amendment, or public rights.

6) The attempted “escape hatch”: later Supreme Court authority

  • FCC v. AT&T (2026): The panel distinguishes this recent Supreme Court case because the FCC statutory scheme provided a trial de novo in DOJ collection suits, whereas the FDCA/TCA scheme bars district-court review of the “validity, amount, and appropriateness” of penalties in collection actions (21 U.S.C. § 333(f)(7)). This distinction underscores why the Fifth Circuit saw the HHS process as the final word on liability and penalty amount—without any jury ever.

B. Legal Reasoning

1) Nondelegation: foreclosed, and major questions does not apply

The court’s nondelegation analysis is short because it is precedent-bound. Under Big Times Vapes, Inc. v. FDA, the deeming provision supplies an intelligible principle: Congress defined “tobacco product,” announced a regulatory policy, and limited FDA’s deeming discretion. TTB’s “major questions” reframing fails because the deeming authority is explicit, and the major-questions doctrine is aimed at agencies exploiting ambiguity. On this view, there is no ambiguity to exploit: Congress said FDA may “deem” additional products.

2) Seventh Amendment: the civil penalty looks like classic “law”

Following SEC v. Jarkesy, the court asks whether the action is “legal in nature” by looking at the remedy and then the cause of action.

  • Remedy (dominant factor): The $19,192 sanction is a civil monetary penalty designed to punish and deter. The opinion stresses penalty-setting factors (gravity, history, culpability, and intent enhancements) and that funds are paid to the U.S. Treasury. Under Jarkesy and Tull v. United States, that is the “prototypical common law remedy,” strongly pointing to a jury-trial right.
  • Cause of action (confirmatory factor): The court analogizes FDA’s “adulterated” and “misbranded” enforcement to common-law actions addressing unwholesome provisions and deceptive representations. The analogical method is explicitly Jarkesy’s: the action need not be identical, only closely related in substance and conduct regulated.

3) Public-rights exception: no historically grounded category for these penalty actions

The central holding is that HHS could not carry its burden to fit this proceeding into a narrow, historically rooted “public rights” category. The court rejects three routes HHS effectively pursued:

  • “Public health” as a category: The majority refuses to treat “public health” regulation as itself a recognized historic carveout from Article III/jury trial. It reads Crowell v. Benson’s mention of public health as dicta and treats Houston v. St. Louis Independent Packing Co. as not addressing the constitutional questions at stake.
  • “Congress can assign it, therefore it’s public”: The court follows Jarkesy’s insistence that assignment is not the test; otherwise, Congress could create an “automatic” public-rights exception whenever it routes claims to agencies.
  • “Novel comprehensive scheme”: Novelty does not defeat the Seventh Amendment. Jarkesy’s point (as applied here) is that statutory innovation does not permit siphoning punitive, legal-in-nature penalty actions away from juries.

The court also emphasizes structural finality: unlike the statute in FCC v. AT&T, the FDCA/TCA collection mechanism blocks any later de novo judicial proceeding on validity or amount. That magnifies the constitutional concern because the agency is not a preliminary screener; it is the adjudicator of last resort on liability and penalty.

4) The dissent’s competing frame

Judge Douglas agrees the Seventh Amendment is implicated but would uphold agency adjudication under the public-rights exception because the specific enforcement action is best understood as enforcing a novel “premarket authorization” requirement—more like modern technical regulatory compliance (with no close common-law analogue) than like common-law fraud or trespass. The dissent’s approach would read the “public rights” line more flexibly in the context of comprehensive health-and-commerce regulatory systems.

C. Impact

  • Immediate practical effect (within the Fifth Circuit): HHS/FDA cannot obtain final civil monetary penalties for unauthorized vape sales through juryless HHS adjudications—at least where the scheme provides no subsequent de novo jury trial. The government will be pushed toward Article III enforcement (e.g., injunction actions under 21 U.S.C. § 332, and potentially penalty actions filed in court if available).
  • Structural leverage point—no de novo backstop: The opinion’s distinction from FCC v. AT&T signals a broader principle: agency penalty systems are constitutionally more vulnerable when the agency decision is effectively unreviewable on the merits in later judicial proceedings.
  • Ripple beyond vaping: The reasoning is not vape-specific; it is penalty-specific. Any HHS (or other agency) civil-penalty regime that (i) is punitive/deterrent, (ii) resembles common-law enforcement, and (iii) lacks a meaningful de novo judicial track, may face heightened Seventh Amendment challenges in the Fifth Circuit post-Jarkesy.
  • Inter-circuit and Supreme Court trajectory: Because the dissent articulates a plausible alternative “novel regulatory scheme/public health” framing, the decision tees up a classic post-Jarkesy fault line: how narrowly “public rights” will be confined when Congress uses agencies to impose monetary penalties.

IV. Complex Concepts Simplified

  • “Deeming provision”: A statutory permission slip allowing FDA to declare (“deem”) new categories of products to be regulated as “tobacco products.” Once “deemed,” those products must comply with tobacco rules, including premarket authorization.
  • Nondelegation / “intelligible principle”: Congress may let agencies fill in details, but it must give a guiding standard. Here, Fifth Circuit precedent says Congress gave enough guidance in the TCA’s structure and definitions.
  • Major questions doctrine: A rule that agencies cannot discover vast new powers in vague or ambiguous statutory text. The court says it doesn’t apply when Congress explicitly granted the power.
  • Seventh Amendment (civil jury trial): Preserves the jury in “suits at common law”—modernly, cases seeking legal remedies like monetary penalties. If the remedy is punitive (punishment/deterrence) rather than compensatory, it strongly points toward a jury-trial right.
  • Public-rights exception: A narrow carveout letting Congress send certain historically executive/legislative matters (like immigration or tariffs) to agency adjudication without juries. The Fifth Circuit held FDCA/TCA civil-penalty enforcement does not fit within those historically recognized buckets.
  • Trial de novo: A “do-over” in court where the judge/jury decides facts anew. The court treated the absence of any de novo path (and the statutory bar on district-court review in collection suits) as crucial: without it, the agency’s no-jury proceeding becomes constitutionally decisive.

V. Conclusion

Texas Tobacco Barn v. HHS establishes a significant Fifth Circuit rule in the post-SEC v. Jarkesy landscape: when HHS/FDA seeks punitive civil monetary penalties for FDCA/TCA violations through a juryless administrative adjudication—and the statutory scheme provides no later de novo judicial proceeding—the Seventh Amendment requires adjudication in an Article III court with a jury. The decision preserves existing Fifth Circuit law upholding the TCA’s deeming delegation, but sharply constrains the government’s ability to impose civil penalties administratively in this regulatory space, forcing a shift toward judicial enforcement or statutory redesign that supplies a constitutionally adequate jury-trial mechanism.